These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 21049730)

  • 21. Impact of palifermin on incidence of oral mucositis and healthcare utilization in children undergoing autologous hematopoietic stem cell transplantation for malignant diseases.
    Vitale KM; Violago L; Cofnas P; Bishop J; Jin Z; Bhatia M; Kung AL; George D; Garvin J; Satwani P
    Pediatr Transplant; 2014 Mar; 18(2):211-6. PubMed ID: 24823628
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy.
    Rosen LS; Abdi E; Davis ID; Gutheil J; Schnell FM; Zalcberg J; Cesano A; Gayko U; Chen MG; Clarke S
    J Clin Oncol; 2006 Nov; 24(33):5194-200. PubMed ID: 17075109
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety, Pharmacokinetics, and Efficacy of Palifermin in Children and Adolescents with Acute Leukemias Undergoing Myeloablative Therapy and Allogeneic Hematopoietic Stem Cell Transplantation: A Pediatric Blood and Marrow Transplant Consortium Trial.
    Morris J; Rudebeck M; Neudorf S; Moore T; Duerst R; Shah AJ; Graham M; Aquino V; Morris C; Olsson B
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1247-1256. PubMed ID: 26968792
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo-controlled study.
    Le QT; Kim HE; Schneider CJ; Muraközy G; Skladowski K; Reinisch S; Chen Y; Hickey M; Mo M; Chen MG; Berger D; Lizambri R; Henke M
    J Clin Oncol; 2011 Jul; 29(20):2808-14. PubMed ID: 21670453
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Palifermin: role in the prevention of chemotherapy- and radiation-induced mucositis.
    McDonnell AM; Lenz KL
    Ann Pharmacother; 2007 Jan; 41(1):86-94. PubMed ID: 17190850
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A supersaturated calcium phosphate solution seems to effectively prevent and treat oral mucositis in haematopoietic stem cell transplanted cancer patients - single centre experience.
    Wasko-Grabowska A; Rzepecki P; Oborska S; Barzal J; Mlot B; Gawronski K; Wasko M; Szczylik C
    J BUON; 2012; 17(2):363-8. PubMed ID: 22740219
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Economic impact of palifermin on the costs of hospitalization for autologous hematopoietic stem-cell transplant: analysis of phase 3 trial results.
    Elting LS; Shih YC; Stiff PJ; Bensinger W; Cantor SB; Cooksley C; Spielberger R; Emmanoulides C
    Biol Blood Marrow Transplant; 2007 Jul; 13(7):806-13. PubMed ID: 17580258
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of keratinocyte growth factor (palifermin) for prevention of oral mucositis in TBI-based allogeneic hematopoietic stem cell transplantation.
    Schmidt V; Niederwieser D; Schenk T; Behre G; Klink A; Pfrepper C; Hinke A; Beelen DW; Junghanss C; Uharek L; Krüger WH; Hochhaus A; Sayer HG;
    Bone Marrow Transplant; 2018 Sep; 53(9):1188-1192. PubMed ID: 29545592
    [No Abstract]   [Full Text] [Related]  

  • 29. In a high-dose melphalan setting, palifermin compared with placebo had no effect on oral mucositis or related patient's burden.
    Blijlevens N; de Château M; Krivan G; Rabitsch W; Szomor A; Pytlik R; Lissmats A; Johnsen HE; de Witte T; Einsele H; Ruutu T; Niederwieser D;
    Bone Marrow Transplant; 2013 Jul; 48(7):966-71. PubMed ID: 23241739
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transient oral cavity and skin complications after mucositis preventing therapy (palifermin) in a patient after allogeneic PBSCT. Case history.
    Grzegorczyk-Jaźwińska A; Kozak I; Karakulska-Prystupiuk E; Rokicka M; Ganowicz E; Dwilewicz-Trojaczek J; Górska R
    Adv Med Sci; 2006; 51 Suppl 1():66-8. PubMed ID: 17460832
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-Term Safety Outcomes in Patients with Hematological Malignancies Undergoing Autologous Hematopoietic Stem Cell Transplantation Treated with Palifermin to Prevent Oral Mucositis.
    Stiff PJ; Leinonen M; Kullenberg T; Rudebeck M; de Chateau M; Spielberger R
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):164-9. PubMed ID: 26303102
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Palifermin-associated papular eruption.
    King B; Knopp E; Galan A; Nuovo G; Tigelaar R; McNiff J
    Arch Dermatol; 2009 Feb; 145(2):179-82. PubMed ID: 19221263
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Palifermin does not influence the incidence and severity of GvHD nor long-term survival of patients with hematological diseases undergoing HSCT.
    Nasilowska-Adamska B; Szydlo R; Rzepecki P; Czyz A; Tomaszewska A; Markiewicz M; Torosian T; Bieniaszewska M; Hellman A; Jedrzejczak WW; Holowiecki J; Komarnicki M; Warzocha K; Marianska B
    Ann Transplant; 2011; 16(4):47-54. PubMed ID: 22210421
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Palifermin as treatment in dose-intense conventional polychemotherapy induced mucositis.
    Hueber AJ; Leipe J; Roesler W; Kalden JR; Kallert S; Rech J
    Haematologica; 2006 Aug; 91(8 Suppl):ECR32. PubMed ID: 16923516
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Palifermin (Kepivance) for myelotoxic-therapy-related mucositis.
    Med Lett Drugs Ther; 2005 Apr; 47(1207):36. PubMed ID: 15843784
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Palifermin in a hematopoietic stem cell transplant patient with osteonecrosis of the jaw.
    Yageman LA; Cronin SM; Peres E; Abidi MH; Ibrahim RB
    J Oncol Pharm Pract; 2006 Jun; 12(2):119-21. PubMed ID: 16984751
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Palifermin, administered for three doses only, reduces mucositis in patients undergoing HSCT and receiving chemoradiotherapy conditioning.
    Coutsouvelis J; Dooley M; Kirkpatrick CM; Avery S; Hopkins R; Spencer A
    Bone Marrow Transplant; 2022 Aug; 57(8):1329-1331. PubMed ID: 35589999
    [No Abstract]   [Full Text] [Related]  

  • 38. Keratinocyte growth factor.
    Athar U; Gentile TC
    Expert Opin Biol Ther; 2009 Jun; 9(6):779-87. PubMed ID: 19456212
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Palifermin is efficacious in recipients of TBI-based but not chemotherapy-based allogeneic hematopoietic stem cell transplants.
    Goldberg JD; Zheng J; Castro-Malaspina H; Jakubowski AA; Heller G; van den Brink MR; Perales MA
    Bone Marrow Transplant; 2013 Jan; 48(1):99-104. PubMed ID: 22750997
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Keratinocyte growth factor in focus: A comprehensive review from structural and functional aspects to therapeutic applications of palifermin.
    Sadeghi S; Kalhor H; Panahi M; Abolhasani H; Rahimi B; Kalhor R; Mehrabi A; Vahdatinia M; Rahimi H
    Int J Biol Macromol; 2021 Nov; 191():1175-1190. PubMed ID: 34606789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.